These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20811671)

  • 1. High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array.
    Yoon MS; Suh DS; Choi KU; Sol MY; Shin DH; Park WY; Lee JH; Jeong SM; Kim WG; Shin NR
    Oncol Rep; 2010 Oct; 24(4):917-25. PubMed ID: 20811671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines.
    Sánchez-Vega F; Gotea V; Petrykowska HM; Margolin G; Krivak TC; DeLoia JA; Bell DW; Elnitski L
    Epigenetics; 2013 Dec; 8(12):1355-72. PubMed ID: 24149212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
    Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of O⁶-methyguanine-DNA methyltransferase by promoter hypermethylation: association of epithelial ovarian carcinogenesis in specific histological types.
    Roh HJ; Suh DS; Choi KU; Yoo HJ; Joo WD; Yoon MS
    J Obstet Gynaecol Res; 2011 Jul; 37(7):851-60. PubMed ID: 21450028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
    Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
    Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
    Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation in the PTCH gene in cervical epithelial cancer and ovarian cancer tissue as studied by eight novel Pyrosequencing® assays.
    Löf-Öhlin ZM; Levanat S; Sabol M; Sorbe B; Nilsson TK
    Int J Oncol; 2011 Mar; 38(3):685-92. PubMed ID: 21206974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
    Ma L; Zhang JH; Liu FR; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of promoter methylation of GATA4 gene in epithelial ovarian cancer.
    Chmelarova M; Dvorakova E; Spacek J; Laco J; Palicka V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Dec; 157(4):294-7. PubMed ID: 24145767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation in the p53 promoter in epithelial ovarian cancer.
    Chmelarova M; Krepinska E; Spacek J; Laco J; Beranek M; Palicka V
    Clin Transl Oncol; 2013 Feb; 15(2):160-3. PubMed ID: 22855178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.
    Losi L; Fonda S; Saponaro S; Chelbi ST; Lancellotti C; Gozzi G; Alberti L; Fabbiani L; Botticelli L; Benhattar J
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29882921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
    Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
    Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
    Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
    Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
    Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
    Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
    Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
    Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.
    Wu Q; Lothe RA; Ahlquist T; Silins I; Tropé CG; Micci F; Nesland JM; Suo Z; Lind GE
    Mol Cancer; 2007 Jul; 6():45. PubMed ID: 17623056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.